Details

Autor(en) / Beteiligte

• García-Arriaza, Juan
• Arnáez, Pilar
• Jiménez, José Luis
• Gómez, Carmen E.
• Muñoz-Fernández, María Ángeles
• Esteban, Mariano

Titel

Vector replication and expression of HIV-1 antigens by the HIV/AIDS vaccine candidate MVA-B is not affected by HIV-1 protease inhibitors

Ist Teil von

• Virus research, 2012-08, Vol.167 (2), p.391-396

Ort / Verlag

Netherlands: Elsevier B.V

Erscheinungsjahr

2012

Quelle

MEDLINE

Beschreibungen/Notizen

• ► Effect of HIV-1 protease inhibitors on the HIV vaccine candidate MVA-B. ► HIV-1 protease inhibitors do not affect MVA-B virus growth kinetics in cultured cells. ► HIV-1 protease inhibitors do not affect MVA-B expression of HIV-1 antigens. ► These results highlight the potential of MVA-B for use in HAART-treated AIDS patients. MVA-B is an attenuated poxvirus vector expressing human immunodeficiency virus type 1 Env, Gag, Pol, and Nef antigens from clade B, and is considered a promising HIV/AIDS vaccine candidate. Recently, a phase I clinical trial in human healthy volunteers has shown that MVA-B is safe and highly immunogenic, inducing broad, polyfunctional, and long-lasting CD4+ and CD8+ T cell responses to HIV-1 antigens, with preference for effector memory T cells; and it also triggers the induction of specific antibodies to Env in most of the vaccines. While MVA recombinants expressing HIV-1 antigens are being used or plan to use in therapeutic clinical trials, little is known on the effect of HIV-1 highly active antiretroviral therapy in MVA life cycle. To define this role, here we have evaluated in established cell cultures and human dendritic cells to what extent different HIV-1 protease inhibitors affect virus replication and expression of HIV-1 antigens during MVA-B infection. The results obtained revealed that the most commonly used HIV-1 protease inhibitors (atazanavir, ritonavir, and lopinavir) had no effect on MVA-B virus growth kinetics, even at higher concentrations than those normally used on HAART. Furthermore, expression of gp120 and the fused Gag-Pol-Nef polyprotein in permissive and non-permissive cells infected with MVA-B were also not affected. These findings are relevant information for the therapeutic use of MVA-B as an HIV-1/AIDS vaccine.